KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Cash from Operations (2016 - 2025)

Boston Scientific (BSX) has disclosed Cash from Operations for 17 consecutive years, with 1364000000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 6.32% to 1364000000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 4534000000.0 through Dec 2025, up 31.99% year-over-year, with the annual reading at 4534000000.0 for FY2025, 31.99% up from the prior year.
  • Cash from Operations hit 1364000000.0 in Q4 2025 for Boston Scientific, up from 1343000000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 1456000000.0 in Q4 2024 to a low of 58000000.0 in Q1 2022.
  • Historically, Cash from Operations has averaged 693400000.0 across 5 years, with a median of 650500000.0 in 2021.
  • Biggest five-year swings in Cash from Operations: soared 468.83% in 2021 and later tumbled 120.42% in 2022.
  • Year by year, Cash from Operations stood at 478000000.0 in 2021, then soared by 68.83% to 807000000.0 in 2022, then grew by 18.59% to 957000000.0 in 2023, then soared by 52.14% to 1456000000.0 in 2024, then decreased by 6.32% to 1364000000.0 in 2025.
  • Business Quant data shows Cash from Operations for BSX at 1364000000.0 in Q4 2025, 1343000000.0 in Q3 2025, and 1286000000.0 in Q2 2025.